Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kim, Aelin"'
Autor:
Osman, Afaf E. G., Mencia-Trinchant, Nuria, Saygin, Caner, Moma, Luke, Kim, Aelin, Housman, Genevieve, Pozsgai, Matthew, Sinha, Eti, Chandra, Pooja, Hassane, Duane C., Sboner, Andrea, Sangani, Kishan, DiNardi, Nick, Johnson, Christopher, Wallace, Sara S., Jabri, Bana, Luu, Hue, Guzman, Monica L., Desai, Pinkal, Godley, Lucy A.
Publikováno v:
In Blood Advances 9 May 2023 7(9):1910-1914
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies
Autor:
Saygin, Caner, Roloff, Gregory, Hahn, Christopher N., Chhetri, Rakchha, Gill, Saar, Elmariah, Hany, Talati, Chetasi, Nunley, Emma, Gao, Guimin, Kim, Aelin, Bishop, Michael, Kosuri, Satyajit, Das, Soma, Singhal, Deepak, Venugopal, Parvathy, Homan, Claire C., Brown, Anna, Scott, Hamish S., Hiwase, Devendra, Godley, Lucy A.
Publikováno v:
In Blood Advances 28 February 2023 7(4):549-554
Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
Autor:
Saygin, Caner, Roloff, Gregory W., Hahn, Christopher N, Chhetri, Rakchha *, Gill, Saar, Elmariah, Hany, Talati, Chetasi *, Nunley, Emma *, Gao, Guimin *, Kim, Aelin *, Bishop, Michael R., Kosuri, Satyajit *, Das, Soma *, Singhal, Deepak *, Venugopal, Parvathy, Homan, Claire *, Brown, Anna L., Scott, Hamish S, Hiwase, Devendra, Godley, Lucy A.
Publikováno v:
In Blood 15 November 2022 140 Supplement 1:10542-10544
Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
Autor:
Caner Saygin, Gregory Roloff, Christopher N. Hahn, Rakchha Chhetri, Saar Gill, Hany Elmariah, Chetasi Talati, Emma Nunley, Guimin Gao, Aelin Kim, Michael Bishop, Satyajit Kosuri, Soma Das, Deepak Singhal, Parvathy Venugopal, Claire C. Homan, Anna Brown, Hamish S. Scott, Devendra Hiwase, Lucy A. Godley
Publikováno v:
Blood. 140:10542-10544
There is increasing recognition that pathogenic germ line variants drive the development of hematopoietic cancers in many individuals. Currently, patients with hereditary hematologic malignancies (HHMs) receive similar standard therapies and hematopo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1fb3e6bfd2c9a78a4988dedb6620dac
https://doi.org/10.1182/blood-2022-167098
https://doi.org/10.1182/blood-2022-167098